TRCT
ATRA icon

Tower Research Capital (TRC)’s Atara Biotherapeutics ATRA Stock Holding History

Tower Research Capital (TRC)’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,737
Closed -$31.4K – 5123
2025
Q4 		$31.4K Buy
1,737
+1,395
+408% +$20.8K ﹤0.01% 2776
2025
Q3 		$4.9K Buy
+342
New +$3.94K ﹤0.01% 4284
2025
Q2 		– Sell
-185
Closed -$1.1K – 5254
2025
Q1 		$1.1K Buy
185
+115
+164% +$1K ﹤0.01% 4771
2024
Q4 		$932 Sell
70
-682
-91% -$7.18K ﹤0.01% 5131
2024
Q3 		$6.11K Sell
752
-3,715
-83% -$31.8K ﹤0.01% 4181
2024
Q2 		$38K Buy
4,467
+4,231
+1,793% +$63.6K ﹤0.01% 3305
2024
Q1 		$4.1K Sell
236
-576
-71% -$10.2K ﹤0.01% 4739
2023
Q4 		$10.4K Buy
812
+486
+149% +$11.3K ﹤0.01% 4252
2023
Q3 		$12.1K Sell
326
-741
-69% -$33K ﹤0.01% 3930
2023
Q2 		$42.9K Buy
1,067
+705
+195% +$39.9K ﹤0.01% 2710
2023
Q1 		$26K Buy
362
+279
+336% +$27.1K ﹤0.01% 3140
2022
Q4 		$7K Sell
83
-635
-88% -$66.2K ﹤0.01% 4525
2022
Q3 		$68K Buy
718
+199
+38% +$22.4K ﹤0.01% 2883
2022
Q2 		$101K Sell
519
-282
-35% -$46K ﹤0.01% 2283
2022
Q1 		$186K Buy
801
+516
+181% +$164K ﹤0.01% 1792
2021
Q4 		$112K Sell
285
-574
-67% -$242K ﹤0.01% 2157
2021
Q3 		$385K Buy
859
+656
+323% +$235K 0.01% 1177
2021
Q2 		$79K Sell
203
-112
-36% -$39.9K ﹤0.01% 2611
2021
Q1 		$113K Sell
315
-45
-13% -$19.9K ﹤0.01% 2498
2020
Q4 		$176K Buy
360
+239
+198% +$110K 0.01% 1818
2020
Q3 		$39K Sell
121
-575
-83% -$196K ﹤0.01% 3636
2020
Q2 		$253K Buy
+696
New +$176K 0.01% 1595
2020
Q1 		– Sell
-175
Closed -$72K – 3025
2019
Q4 		$72K Buy
175
+61
+54% +$21K 0.01% 1124
2019
Q3 		$40K Buy
+114
New +$42.5K ﹤0.01% 1953
2019
Q2 		– Sell
-3
Closed -$3K – 3652
2019
Q1 		$3K Hold
3
– – ﹤0.01% 3257
2018
Q4 		$3K Sell
3
-96
-97% -$89.2K ﹤0.01% 3145
2018
Q3 		$103K Buy
+99
New +$96.8K 0.01% 1324
2018
Q2 		– Sell
-219
Closed -$213K – 3621
2018
Q1 		$213K Buy
+219
New +$200K 0.02% 847
2017
Q4 		– Sell
-50
Closed -$21K – 3499
2017
Q3 		$21K Buy
50
+46
+1,150% +$17.3K ﹤0.01% 2692
2017
Q2 		$1K Buy
+4
New +$1.54K ﹤0.01% 2457
2017
Q1 		– Sell
-22
Closed -$8K – 3038
2016
Q4 		$8K Buy
+22
New +$9.31K ﹤0.01% 2762
2016
Q1 		– Sell
-4
Closed -$3K – 4089
2015
Q4 		$3K Sell
4
-116
-97% -$87.7K ﹤0.01% 3385
2015
Q3 		$94K Buy
120
+112
+1,400% +$137K 0.01% 604
2015
Q2 		$11K Buy
8
+1
+14% +$1.15K ﹤0.01% 2601
2015
Q1 		$8K Sell
7
-37
-84% -$24.5K ﹤0.01% 2936
2014
Q4 		$29K Buy
+44
New +$26.9K ﹤0.01% 1348

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s ATRA Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 1,737 shares — an estimated $31.4K sold.

Tower Research Capital (TRC) first reported a position in ATRA in Q4 2014 and held it in 36 quarters. The position peaked at $385K in Q3 2021. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,737 Atara Biotherapeutics shares in Q1 2026, an estimated $31.4K.
  • Tower Research Capital (TRC) first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 36 quarters.
  • Tower Research Capital (TRC)'s Atara Biotherapeutics position peaked at $385K in Q3 2021.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.